Get the Stockscreener App
3.13
2.62%
0.08
After Hours:
3.14
0.01
+0.32%
Mural Oncology Plc stock is traded at $3.13, with a volume of 131.13K.
It is up +2.62% in the last 24 hours and down -5.72% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$3.05
Open:
$3.08
24h Volume:
131.13K
Relative Volume:
0.90
Market Cap:
$54.35M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.69%
1M Performance:
-5.72%
6M Performance:
-35.99%
1Y Performance:
+0.00%
1-Day Range:
$3.0611
$3.22
1-Week Range:
$3.00
$3.3388
52-Week Range:
$2.88
$6.00
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Mural Oncology Plc Stock (MURA) Latest News
Mural Oncology Highlights Clinical Trials During It's Maiden Investor Day - Forbes
1,688,000 Shares in Mural Oncology plc (NASDAQ:MURA) Acquired by Armistice Capital LLC - MarketBeat
Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress - The Manila Times
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress - StockTitan
Mural Oncology appoints new board member amid growth phase - Investing.com
Mural Oncology appoints new director and audit chair - Investing.com
Mural Oncology Appoints Sachiyo Minegishi To Board - citybiz
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi - StockTitan
Primecap Management Co. CA Purchases Shares of 235,551 Mural Oncology plc (NASDAQ:MURA) - MarketBeat
Primecap Management Co. CA Buys New Holdings in Mural Oncology plc (NASDAQ:MURA) - Defense World
Acadian Asset Management LLC Takes $998,000 Position in Mural Oncology plc (NASDAQ:MURA) - MarketBeat
Acadian Asset Management LLC Buys Shares of 318,536 Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology to Host First Virtual Investor Day on September 26, 2024 - ForexTV.com
Mural Oncology to Host First Virtual Investor Day on September 26, 2024 - EIN News
Mural Oncology to Host First Virtual Investor Day on September 26, 2024 - StockTitan
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
MURAMural Oncology plc Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mural Oncology to Present at Two Upcoming Investor Conferences - ForexTV.com
Mural Oncology to Present at Two Upcoming Investor Conferences - StockTitan
Mural Oncology plc (NASDAQ:MURA) Sees Significant Decrease in Short Interest - MarketBeat
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress - BioSpace
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress - wallstreet:online
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress - StockTitan
Harbor Capital Advisors Inc. Takes Position in Mural Oncology plc (NASDAQ:MURA) - Defense World
Critical Analysis: Mural Oncology (NASDAQ:MURA) & Kamada (NASDAQ:KMDA) - Defense World
Mural Oncology Appoints George Golumbeski, Ph.D., to its Board of Directors - citybiz
Mural Oncology appoints new independent director By Investing.com - Investing.com Nigeria
Mural Oncology appoints George Golumbeski to board - Investing.com
Mural Oncology appoints new independent director - Investing.com India
Mural Oncology appoints new independent director - Investing.com
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors - ForexTV.com
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors - StockTitan
Head to Head Survey: Mural Oncology (NASDAQ:MURA) and Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mural Oncology plc (NASDAQ:MURA) Short Interest Down 18.4% in June - Defense World
Short Interest in Mural Oncology plc (NASDAQ:MURA) Declines By 18.4% - MarketBeat
Evaluating MURA’s financial ratios for a profitable investment - US Post News
Mural Oncology plc (NASDAQ:MURA) CEO Caroline Loew Sells 12,531 Shares of Stock - Defense World
Mural Oncology plc (NASDAQ:MURA) CEO Caroline Loew Sells 12,531 Shares - MarketBeat
Mural Oncology reports inducement grants under Nasdaq listing rule - Medical Buyer
Nothing is Better Than Mural Oncology plc (MURA) stock at the moment - SETE News
Rodman & Renshaw Begins Coverage on Mural Oncology (NASDAQ:MURA) - MarketBeat
Mural Oncology (NASDAQ:MURA) Trading Up 0.3% - MarketBeat
Mural Oncology (NASDAQ:MURA) Trading 0.3% Higher - Defense World
Views of Wall Street's Leading Experts on Mural Oncology plc – Sete News - SETE News
Mural to Present and Host 1×1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference - ForexTV.com
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference - GlobeNewswire Inc.
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Mural Oncology plc (NASDAQ:MURA) Sees Significant Decline in Short Interest - MarketBeat
Closing Figures: Mural Oncology plc (MURA)'s Negative Finish at 3.35, Down -6.42 – DWinneX - The Dwinnex
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting - ForexTV.com
Mural Oncology (NASDAQ:MURA) Stock Price Down 3.3% - Defense World
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):